Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications.

[1]  Richard J. Edwards,et al.  Metabotropic Glutamate Receptors , 2015, The Journal of Biological Chemistry.

[2]  Sarah L. Huszar,et al.  Mechanism based neurotoxicity of mGlu5 positive allosteric modulators – Development challenges for a promising novel antipsychotic target , 2014, Neuropharmacology.

[3]  Jens Meiler,et al.  Structure of a Class C GPCR Metabotropic Glutamate Receptor 1 Bound to an Allosteric Modulator , 2014, Science.

[4]  Kari A. Johnson,et al.  Selective Actions of Novel Allosteric Modulators Reveal Functional Heteromers of Metabotropic Glutamate Receptors in the CNS , 2014, The Journal of Neuroscience.

[5]  Julie L. Engers,et al.  Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM). , 2013, Journal of medicinal chemistry.

[6]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[7]  Hwi-young Cho,et al.  Peripheral group II and III metabotropic glutamate receptors in the knee joint attenuate carrageenan-induced nociceptive behavior in rats , 2013, Neuroscience Letters.

[8]  K. Gregory,et al.  A Novel Metabotropic Glutamate Receptor 5 Positive Allosteric Modulator Acts at a Unique Site and Confers Stimulus Bias to mGlu5 Signaling , 2013, Molecular Pharmacology.

[9]  T. Barber,et al.  Somatic Mutations in GRM1 in Cancer Alter Metabotropic Glutamate Receptor 1 Intracellular Localization and Signaling , 2013, Molecular Pharmacology.

[10]  F. Dudek,et al.  Unique Signaling Profiles of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Determine Differences in In Vivo Activity , 2013, Biological Psychiatry.

[11]  Julie L. Engers,et al.  Development of the First Selective mGlu3 NAM from an mGlu5 PAM Hit , 2013 .

[12]  Kari A. Johnson,et al.  The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease , 2013, Neuropharmacology.

[13]  P. Gubellini,et al.  Synergy between l-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: Implications for Parkinson's disease treatment and dyskinesia , 2013, Neuropharmacology.

[14]  P. Conn,et al.  Functional selectivity induced by mGlu4 receptor positive allosteric modulation and concomitant activation of Gq coupled receptors , 2013, Neuropharmacology.

[15]  T. Salt,et al.  ADX71743, a Potent and Selective Negative Allosteric Modulator of Metabotropic Glutamate Receptor 7: In Vitro and In Vivo Characterization , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[16]  G. Marek,et al.  CNS distribution of metabotropic glutamate 2 and 3 receptors: Transgenic mice and [3H]LY459477 autoradiography , 2013, Neuropharmacology.

[17]  Takahiro Yamashita,et al.  Glutamate Acts as a Partial Inverse Agonist to Metabotropic Glutamate Receptor with a Single Amino Acid Mutation in the Transmembrane Domain* , 2013, The Journal of Biological Chemistry.

[18]  J. Guadagno,et al.  Role of metabotropic glutamate receptor 5 signaling and homer in oxygen glucose deprivation-mediated astrocyte apoptosis , 2013, Molecular Brain.

[19]  D. Surmeier,et al.  The pathology roadmap in Parkinson disease , 2013, Prion.

[20]  S. Sealfon,et al.  Identification of Three Residues Essential for 5-Hydroxytryptamine 2A-Metabotropic Glutamate 2 (5-HT2A·mGlu2) Receptor Heteromerization and Its Psychoactive Behavioral Function* , 2012, The Journal of Biological Chemistry.

[21]  Andrew S. Felts,et al.  Investigating Metabotropic Glutamate Receptor 5 Allosteric Modulator Cooperativity, Affinity, and Agonism: Enriching Structure-Function Studies and Structure-Activity Relationships , 2012, Molecular Pharmacology.

[22]  A. Dilella,et al.  A Potent and Selective Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator Improves Movement in Rodent Models of Parkinson's Disease , 2012, Journal of Pharmacology and Experimental Therapeutics.

[23]  J. Pin,et al.  Distinct roles of metabotropic glutamate receptor dimerization in agonist activation and G-protein coupling , 2012, Proceedings of the National Academy of Sciences.

[24]  P. Kammermeier.  Functional and Pharmacological Characteristics of Metabotropic Glutamate Receptors 2/4 Heterodimers , 2012, Molecular Pharmacology.

[25]  Carsten Hoffmann,et al.  Sequential Inter- and Intrasubunit Rearrangements During Activation of Dimeric Metabotropic Glutamate Receptor 1 , 2012, Science Signaling.

[26]  M. Betts,et al.  Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6‐hydroxydopamine rat model of Parkinson's disease , 2012, British journal of pharmacology.

[27]  Cody J. Wenthur,et al.  Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM. , 2012, Bioorganic & medicinal chemistry letters.

[28]  J. Pin,et al.  Stability of GABAB receptor oligomers revealed by dual TR‐FRET and drug‐induced cell surface targeting , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  F. Nicoletti,et al.  Cinnabarinic Acid, an Endogenous Metabolite of the Kynurenine Pathway, Activates Type 4 Metabotropic Glutamate Receptors , 2012, Molecular Pharmacology.

[30]  H. Daniel,et al.  A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  M. Bear,et al.  Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice , 2012, Neuron.

[32]  T. Robbins,et al.  Selective Remediation of Reversal Learning Deficits in the Neurodevelopmental MAM Model of Schizophrenia by a Novel mGlu5 Positive Allosteric Modulator , 2012, Neuropsychopharmacology.

[33]  R. Enz.  Structure of metabotropic glutamate receptor C-terminal domains in contact with interacting proteins , 2012, Front. Mol. Neurosci..

[34]  E. Baca-García,et al.  New perspectives in glutamate and anxiety , 2012, Pharmacology Biochemistry and Behavior.

[35]  Anna L. Blobaum,et al.  The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU0364770 Produces Efficacy Alone and in Combination with l-DOPA or an Adenosine 2A Antagonist in Preclinical Rodent Models of Parkinson's Disease , 2012, Journal of Pharmacology and Experimental Therapeutics.

[36]  Zhen Yan,et al.  Regulation of N-Methyl-d-aspartic Acid (NMDA) Receptors by Metabotropic Glutamate Receptor 7*♦ , 2012, The Journal of Biological Chemistry.

[37]  P. Worley,et al.  Disrupted mGluR5-Homer scaffolds mediate abnormal mGluR5 signaling, circuit function and behavior in a mouse model of Fragile X Syndrome , 2012, Nature Neuroscience.

[38]  R. Quirion,et al.  Successful Cognitive Aging in Rats: A Role for mGluR5 Glutamate Receptors, Homer 1 Proteins and Downstream Signaling Pathways , 2012, PloS one.

[39]  P. Sexton,et al.  Probe Dependence in the Allosteric Modulation of a G Protein-Coupled Receptor: Implications for Detection and Validation of Allosteric Ligand Effects , 2012, Molecular Pharmacology.

[40]  C. Bissantz,et al.  Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators , 2011, British journal of pharmacology.

[41]  Brittney S. Bates,et al.  (3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): Discovery of a new tool compound with activity in the OSS mouse model of addiction. , 2011, ACS chemical neuroscience.

[42]  Danny G. Winder,et al.  Opposing roles of mGluR8 in measures of anxiety involving non-social and social challenges , 2011, Behavioural Brain Research.

[43]  J. Dwyer,et al.  The Metabotropic Glutamate Receptor 7 Allosteric Modulator AMN082: A Monoaminergic Agent in Disguise? , 2011, Journal of Pharmacology and Experimental Therapeutics.

[44]  C. Lindsley,et al.  Discovery of molecular switches within the ADX-47273 mGlu5 PAM scaffold that modulate modes of pharmacology to afford potent mGlu5 NAMs, PAMs and partial antagonists. , 2011, Bioorganic & medicinal chemistry letters.

[45]  P Jeffrey Conn,et al.  "Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology. , 2011, Biochemistry.

[46]  P. Sexton,et al.  Impact of species variability and ‘probe‐dependence’ on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor , 2011, British journal of pharmacology.

[47]  E. Nisenbaum,et al.  Targeting Group II Metabotropic Glutamate (mGlu) Receptors for the Treatment of Psychosis Associated with Alzheimer's Disease: Selective Activation of mGlu2 Receptors Amplifies β-Amyloid Toxicity in Cultured Neurons, Whereas Dual Activation of mGlu2 and mGlu3 Receptors Is Neuroprotective , 2011, Molecular Pharmacology.

[48]  C. Becker,et al.  Structural characterization of intracellular C‐terminal domains of group III metabotropic glutamate receptors , 2011, FEBS letters.

[49]  P. Calabresi,et al.  Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. , 2011, Brain : a journal of neurology.

[50]  Janice Branson,et al.  Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056 , 2011, Science Translational Medicine.

[51]  Eric Trinquet,et al.  A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  G. Marek,et al.  N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a Novel Metabotropic Glutamate 2 Potentiator with Potential Anxiolytic/Antidepressant Properties: In Vivo Profiling Suggests a Link between Behavioral and Central Nervous System Neu , 2011, Journal of Pharmacology and Experimental Therapeutics.

[53]  P Jeffrey Conn,et al.  Discovery of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Reveals Chemical and Functional Diversity and In Vivo Activity in Rat Behavioral Models of Anxiolytic and Antipsychotic Activity , 2010, Molecular Pharmacology.

[54]  S. Schann,et al.  Chemical switch of a metabotropic glutamate receptor 2 silent allosteric modulator into dual metabotropic glutamate receptor 2/3 negative/positive allosteric modulators. , 2010, Journal of medicinal chemistry.

[55]  S. Jadhav,et al.  Discovery of N-Aryl Piperazines as Selective mGluR5 Potentiators with Improved In Vivo Utility , 2010 .

[56]  R. Duvoisin,et al.  Acute pharmacological modulation of mGluR8 reduces measures of anxiety , 2010, Behavioural Brain Research.

[57]  L. Khaodhiar,et al.  Metabolic syndrome with the atypical antipsychotics. , 2010, Current opinion in endocrinology, diabetes, and obesity.

[58]  Ariel Y Deutch,et al.  Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss. , 2010, Cerebral cortex.

[59]  K. Gregory,et al.  Discovery of a Novel Chemical Class of mGlu5 Allosteric Ligands with Distinct Modes of Pharmacology , 2010, ACS chemical neuroscience.

[60]  S. Bicciato,et al.  Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation , 2010, Nature Medicine.

[61]  P. Kammermeier,et al.  Venus fly trap domain of mGluR1 functions as a dominant negative against group I mGluR signaling. , 2010, Journal of neurophysiology.

[62]  C. Lindsley,et al.  Re-exploration of the PHCCC Scaffold: Discovery of Improved Positive Allosteric Modulators of mGluR4. , 2010, ACS chemical neuroscience.

[63]  P. S. St George-Hyslop,et al.  Group II Metabotropic Glutamate Receptor Stimulation Triggers Production and Release of Alzheimer's Amyloid β42 from Isolated Intact Nerve Terminals , 2010, The Journal of Neuroscience.

[64]  Kari A. Johnson,et al.  Context-Dependent Pharmacology Exhibited by Negative Allosteric Modulators of Metabotropic Glutamate Receptor 7 , 2010, Molecular Pharmacology.

[65]  P. Conn,et al.  Metabotropic glutamate receptors: physiology, pharmacology, and disease. , 2010, Annual review of pharmacology and toxicology.

[66]  P Jeffrey Conn,et al.  Glutamate receptors as therapeutic targets for Parkinson's disease. , 2009, CNS & neurological disorders drug targets.

[67]  P. Gubellini,et al.  Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[68]  S. Ozaki,et al.  Identification of a novel transmembrane domain involved in the negative modulation of mGluR1 using a newly discovered allosteric mGluR1 antagonist, 3-cyclohexyl-5-fluoro-6-methyl-7-(2-morpholin-4-ylethoxy)-4H-chromen-4-one , 2009, Neuropharmacology.

[69]  C. Lindsley,et al.  Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl)pyrimidines. , 2009, Journal of medicinal chemistry.

[70]  V. Mutel,et al.  Fluorinated 9H-xanthene-9-carboxylic acid oxazol-2-yl-amides as potent, orally available mGlu1 receptor enhancers. , 2009, Bioorganic & medicinal chemistry letters.

[71]  C. Lindsley,et al.  Discovery and Characterization of Novel Allosteric Potentiators of M1 Muscarinic Receptors Reveals Multiple Modes of Activity , 2009, Molecular Pharmacology.

[72]  D. Nguyen,et al.  A pilot open label, single dose trial of fenobam in adults with fragile X syndrome , 2009, Journal of Medical Genetics.

[73]  F. Liu,et al.  ADX47273 [S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities , 2008, Journal of Pharmacology and Experimental Therapeutics.

[74]  Kari A. Johnson,et al.  Discovery, Characterization, and Antiparkinsonian Effect of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4 , 2008, Molecular Pharmacology.

[75]  C. Lindsley,et al.  Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators. , 2008, Bioorganic & medicinal chemistry letters.

[76]  J. Erickson,et al.  Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder , 2008, Neuropsychopharmacology.

[77]  J. Bockaert,et al.  Knock-In Mice Lacking the PDZ-Ligand Motif of mGluR7a Show Impaired PKC-Dependent Autoinhibition of Glutamate Release, Spatial Working Memory Deficits, and Increased Susceptibility to Pentylenetetrazol , 2008, The Journal of Neuroscience.

[78]  R. Huganir,et al.  PICK1 uncoupling from mGluR7a causes absence-like seizures , 2008, Nature Neuroscience.

[79]  P. Kammermeier,et al.  The mGlu(4) receptor allosteric modulator N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide acts as a direct agonist at mGlu(6) receptors. , 2008, European journal of pharmacology.

[80]  L. Lubbers,et al.  Transposition of Three Amino Acids Transforms the Human Metabotropic Glutamate Receptor (mGluR)-3-Positive Allosteric Modulation Site to mGluR2, and Additional Characterization of the mGluR2-Positive Allosteric Modulation Site , 2008, Journal of Pharmacology and Experimental Therapeutics.

[81]  D. Schoepp,et al.  Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (–)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039) , 2008, Journal of Pharmacology and Experimental Therapeutics.

[82]  Young Ho Suh,et al.  Corequirement of PICK1 Binding and PKC Phosphorylation for Stable Surface Expression of the Metabotropic Glutamate Receptor mGluR7 , 2008, Neuron.

[83]  J. Kew,et al.  Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 3. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists. , 2008, Bioorganic & medicinal chemistry letters.

[84]  Stephen T Warren,et al.  Fragile X syndrome , 2008, European Journal of Human Genetics.

[85]  Kari A. Johnson,et al.  A Novel Assay of Gi/o-Linked G Protein-Coupled Receptor Coupling to Potassium Channels Provides New Insights into the Pharmacology of the Group III Metabotropic Glutamate Receptors , 2008, Molecular Pharmacology.

[86]  P. Conn,et al.  Group III mGluR regulation of synaptic transmission at the SC-CA1 synapse is developmentally regulated , 2008, Neuropharmacology.

[87]  J. Jankovic.  Parkinson’s disease: clinical features and diagnosis , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[88]  Graeme Milligan,et al.  Identification of a serotonin/glutamate receptor complex implicated in psychosis , 2008, Nature.

[89]  P. Jeffrey Conn,et al.  N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) Acts through a Novel Site as a Positive Allosteric Modulator of Group 1 Metabotropic Glutamate Receptors , 2008, Molecular Pharmacology.

[90]  K. M. Huber,et al.  Homer Interactions Are Necessary for Metabotropic Glutamate Receptor-Induced Long-Term Depression and Translational Activation , 2008, The Journal of Neuroscience.

[91]  Mark F. Bear,et al.  Correction of Fragile X Syndrome in Mice , 2007, Neuron.

[92]  Jack J. Chen,et al.  Pharmacotherapy for Parkinson's Disease , 2007, Pharmacotherapy.

[93]  J. Pin,et al.  Activation of a Dimeric Metabotropic Glutamate Receptor by Intersubunit Rearrangement* , 2007, Journal of Biological Chemistry.

[94]  G. Suzuki,et al.  In Vitro Pharmacological Characterization of Novel Isoxazolopyridone Derivatives as Allosteric Metabotropic Glutamate Receptor 7 Antagonists , 2007, Journal of Pharmacology and Experimental Therapeutics.

[95]  S. Mosolov,et al.  Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.

[96]  M. Liechti,et al.  Metabotropic Glutamate 2/3 Receptors in the Ventral Tegmental Area and the Nucleus Accumbens Shell Are Involved in Behaviors Relating to Nicotine Dependence , 2007, The Journal of Neuroscience.

[97]  Christina Zeitz,et al.  Night blindness–associated mutations in the ligand‐binding, cysteine‐rich, and intracellular domains of the metabotropic glutamate receptor 6 abolish protein trafficking , 2007, Human mutation.

[98]  P. Sexton,et al.  Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. , 2007, Trends in pharmacological sciences.

[99]  Z. Xiang,et al.  A Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 2 Blocks a Hallucinogenic Drug Model of Psychosis , 2007, Molecular Pharmacology.

[100]  P. Flor,et al.  Activation of the mGlu7 receptor elicits antidepressant-like effects in mice , 2007, Psychopharmacology.

[101]  P. Conn,et al.  A Novel Family of Potent Negative Allosteric Modulators of Group II Metabotropic Glutamate Receptors , 2007, Journal of Pharmacology and Experimental Therapeutics.

[102]  Hisashi Ohta,et al.  Pharmacological Characterization of a New, Orally Active and Potent Allosteric Metabotropic Glutamate Receptor 1 Antagonist, 4-[1-(2-Fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC) , 2007, Journal of Pharmacology and Experimental Therapeutics.

[103]  J. Pin,et al.  Interaction of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 with the Negative Allosteric Antagonist Site Is Required for Potentiation of Receptor Responses , 2007, Molecular Pharmacology.

[104]  K. Perry,et al.  In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders , 2007, Psychopharmacology.

[105]  Takanori Muto,et al.  Structures of the extracellular regions of the group II/III metabotropic glutamate receptors , 2007, Proceedings of the National Academy of Sciences.

[106]  Y. Shaham,et al.  Systemic and Central Amygdala Injections of the mGluR2/3 Agonist LY379268 Attenuate the Expression of Incubation of Cocaine Craving , 2007, Biological Psychiatry.

[107]  Arthur Christopoulos,et al.  Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.

[108]  K. Sabapathy,et al.  JNK1 contributes to metabotropic glutamate receptor‐dependent long‐term depression and short‐term synaptic plasticity in the mice area hippocampal CA1 , 2007, The European journal of neuroscience.

[109]  Y. Shaham,et al.  Activation of Group II Metabotropic Glutamate Receptors in the Nucleus Accumbens Shell Attenuates Context-Induced Relapse to Heroin Seeking , 2006, Neuropsychopharmacology.

[110]  L. Barrier,et al.  Group I metabotropic glutamate receptors activate the p70S6 kinase via both mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase (ERK 1/2) signaling pathways in rat striatal and hippocampal synaptoneurosomes , 2006, Neurochemistry International.

[111]  David E. Gloriam,et al.  Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. , 2006, Genomics.

[112]  P. Conn,et al.  A Novel Class of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 1 Interact with a Site Distinct from That of Negative Allosteric Modulators , 2006, Molecular Pharmacology.

[113]  F. Nicoletti,et al.  Pharmacological Activation of mGlu4 Metabotropic Glutamate Receptors Reduces Nigrostriatal Degeneration in Mice Treated with 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine , 2006, The Journal of Neuroscience.

[114]  P. Conn,et al.  Biphenyl-indanone A, a Positive Allosteric Modulator of the Metabotropic Glutamate Receptor Subtype 2, Has Antipsychotic- and Anxiolytic-Like Effects in Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.

[115]  A. Faden,et al.  Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. , 2006, CNS drug reviews.

[116]  J. Peters,et al.  The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine- and food-seeking behavior in rats , 2006, Psychopharmacology.

[117]  Paul J. Harrison,et al.  Alternative splicing of human metabotropic glutamate receptor 3 , 2006, Journal of neurochemistry.

[118]  P. Calabresi,et al.  Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism , 2005, Neuroscience.

[119]  J. Cryan,et al.  A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[120]  P. Conn,et al.  Allosteric Potentiators of Metabotropic Glutamate Receptor Subtype 5 Have Differential Effects on Different Signaling Pathways in Cortical Astrocytes , 2005, Journal of Pharmacology and Experimental Therapeutics.

[121]  P. Jeffrey Conn,et al.  A Close Structural Analog of 2-Methyl-6-(phenylethynyl)-pyridine Acts as a Neutral Allosteric Site Ligand on Metabotropic Glutamate Receptor Subtype 5 and Blocks the Effects of Multiple Allosteric Modulators , 2005, Molecular Pharmacology.

[122]  William Thomsen,et al.  Functional assays for screening GPCR targets. , 2005, Current opinion in biotechnology.

[123]  P. Conn,et al.  A Selective Allosteric Potentiator of Metabotropic Glutamate (mGlu) 2 Receptors Has Effects Similar to an Orthosteric mGlu2/3 Receptor Agonist in Mouse Models Predictive of Antipsychotic Activity , 2005, Journal of Pharmacology and Experimental Therapeutics.

[124]  T. Kenakin.  New Concepts in Drug Discovery: Collateral Efficacy and Permissive Antagonism , 2005, Nature Reviews Drug Discovery.

[125]  Jens-Uwe Peters,et al.  Fenobam: A Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive mGlu5 Receptor Antagonist with Inverse Agonist Activity , 2005, Journal of Pharmacology and Experimental Therapeutics.

[126]  Seiji Tamura,et al.  Radioligand Binding Properties and Pharmacological Characterization of 6-Amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide (YM-298198), a High-Affinity, Selective, and Noncompetitive Antagonist of Metabotropic Glutamate Receptor Type 1 , 2005, Journal of Pharmacology and Experimental Therapeutics.

[127]  J. M. Mathiesen,et al.  Identification of Indole Derivatives Exclusively Interfering with a G Protein-Independent Signaling Pathway of the Prostaglandin D2 Receptor CRTH2 , 2005, Molecular Pharmacology.

[128]  Francine Acher,et al.  Asymmetric Functioning of Dimeric Metabotropic Glutamate Receptors Disclosed by Positive Allosteric Modulators* , 2005, Journal of Biological Chemistry.

[129]  S. Ikeda,et al.  Coupling of Metabotropic Glutamate Receptor 8 to N-Type Ca2+ Channels in Rat Sympathetic Neurons , 2005, Molecular Pharmacology.

[130]  M. Bures,et al.  Methyl substitution of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist. , 2005, Journal of medicinal chemistry.

[131]  C. Lindsley,et al.  A Novel Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Has in Vivo Activity and Antipsychotic-Like Effects in Rat Behavioral Models , 2005, Journal of Pharmacology and Experimental Therapeutics.

[132]  E. Nisenbaum,et al.  Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s) , 2005, Psychopharmacology.

[133]  L. Prézeau,et al.  Evidence for a single heptahelical domain being turned on upon activation of a dimeric GPCR , 2005, The EMBO journal.

[134]  Michael F. Green,et al.  Identification of separable cognitive factors in schizophrenia , 2004, Schizophrenia Research.

[135]  X. Langlois,et al.  JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist , 2004, Neuropharmacology.

[136]  R. Liberman,et al.  Drug and psychosocial curricula for psychiatry residents for treatment of schizophrenia: part I. , 2004, Psychiatric services.

[137]  Philippe Marin,et al.  GPCR-GIP networks: a first step in the discovery of new therapeutic drugs? , 2004, Current opinion in drug discovery & development.

[138]  J. Greenwood,et al.  Mutation-induced Quisqualic Acid and Ibotenic Acid Affinity at the Metabotropic Glutamate Receptor Subtype 4 , 2004, Journal of Biological Chemistry.

[139]  L. Prézeau,et al.  Closed state of both binding domains of homodimeric mGlu receptors is required for full activity , 2004, Nature Structural &Molecular Biology.

[140]  Mark F Bear,et al.  The mGluR theory of fragile X mental retardation , 2004, Trends in Neurosciences.

[141]  P. Calabresi,et al.  Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism. , 2004, Brain : a journal of neurology.

[142]  J. Bockaert,et al.  Identification and functional roles of metabotropic glutamate receptor-interacting proteins. , 2004, Seminars in cell & developmental biology.

[143]  P Jeffrey Conn,et al.  A Novel Selective Allosteric Modulator Potentiates the Activity of Native Metabotropic Glutamate Receptor Subtype 5 in Rat Forebrain , 2004, Journal of Pharmacology and Experimental Therapeutics.

[144]  R. Duvoisin,et al.  Divalent cations modulate the activity of metabotropic glutamate receptors , 2004, Journal of neuroscience research.

[145]  D. Javitt,et al.  Comparative effects of glycine and d-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis , 2004, Schizophrenia Research.

[146]  D. Javitt,et al.  High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia , 2004, Biological Psychiatry.

[147]  S. Duty,et al.  Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine‐treated rat , 2004, British journal of pharmacology.

[148]  H. Kita,et al.  Activation of group III metabotropic glutamate receptors presynaptically reduces both GABAergic and glutamatergic transmission in the rat globus pallidus , 2003, Neuroscience.

[149]  Francine Acher,et al.  Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[150]  I. Vranesic,et al.  (−)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection , 2003, Neuropharmacology.

[151]  E. Nagata,et al.  PI3 kinase enhancer–Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis , 2003, Nature Neuroscience.

[152]  A. Dilella,et al.  Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[153]  L. Bristow,et al.  Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. , 2003, Molecular pharmacology.

[154]  L. Prézeau,et al.  The Second Intracellular Loop of Metabotropic Glutamate Receptors Recognizes C Termini of G-protein α-Subunits* , 2003, Journal of Biological Chemistry.

[155]  P Jeffrey Conn,et al.  A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. , 2003, Molecular pharmacology.

[156]  P Jeffrey Conn,et al.  Group III Metabotropic Glutamate Receptor-Mediated Modulation of the Striatopallidal Synapse , 2003, The Journal of Neuroscience.

[157]  P. Conn,et al.  G protein-coupled receptor kinases regulate metabotropic glutamate receptor 5 function and expression , 2003, Neuropharmacology.

[158]  Paul Greengard,et al.  Loss of bidirectional striatal synaptic plasticity in L-DOPA–induced dyskinesia , 2003, Nature Neuroscience.

[159]  A. Porcellini,et al.  Role of G Protein-coupled Receptor Kinase 4 and β-Arrestin 1 in Agonist-stimulated Metabotropic Glutamate Receptor 1 Internalization and Activation of Mitogen-activated Protein Kinases* , 2003, The Journal of Biological Chemistry.

[160]  J. Kew,et al.  Mutational Analysis and Molecular Modeling of the Allosteric Binding Site of a Novel, Selective, Noncompetitive Antagonist of the Metabotropic Glutamate 1 Receptor* , 2003, The Journal of Biological Chemistry.

[161]  Mark Washburn,et al.  3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. , 2003, Journal of medicinal chemistry.

[162]  L. Levine,et al.  LY354740, an mGlu2/3 Receptor Agonist as a Novel Approach to Treat Anxiety/Stress , 2003, Stress.

[163]  H. Jones,et al.  Dopamine and antipsychotic drug action revisited , 2002, British Journal of Psychiatry.

[164]  E. Nisenbaum,et al.  Modulation of lateral perforant path excitatory responses by metabotropic glutamate 8 (mGlu8) receptors , 2002, Neuropharmacology.

[165]  K. Mangano,et al.  Activation of Group III Metabotropic Glutamate Receptors Inhibits the Production of RANTES in Glial Cell Cultures , 2002, The Journal of Neuroscience.

[166]  H. L. Schulz,et al.  Characterization of three novel isoforms of the metabotrobic glutamate receptor 7 (GRM7) , 2002, Neuroscience Letters.

[167]  R. Gereau,et al.  Metabotropic glutamate receptor involvement in models of acute and persistent pain: prospects for the development of novel analgesics. , 2002, Current drug targets. CNS and neurological disorders.

[168]  Mark F. Bear,et al.  Altered synaptic plasticity in a mouse model of fragile X mental retardation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[169]  H. Ohashi,et al.  A Novel Binding Assay For Metabotropic Glutamate Receptors Using [3H] ʟ-Quisqualic Acid And Recombinant Receptors , 2002, Zeitschrift fur Naturforschung. C, Journal of biosciences.

[170]  P. Somogyi,et al.  Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS , 2002, Neuroscience.

[171]  N. Kunishima,et al.  Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd3+ , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[172]  P. H. Anborgh,et al.  Agonist-stimulated and tonic internalization of metabotropic glutamate receptor 1a in human embryonic kidney 293 cells: agonist-stimulated endocytosis is beta-arrestin1 isoform-specific. , 2001, Molecular pharmacology.

[173]  R A Challiss,et al.  Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors. , 2001, The Biochemical journal.

[174]  J. Kemp,et al.  Positive allosteric modulators of metabotropic glutamate 1 receptor: Characterization, mechanism of action, and binding site , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[175]  Robert J. Lefkowitz,et al.  Classical and new roles of β-arrestins in the regulation of G-PROTEIN-COUPLED receptors , 2001, Nature Reviews Neuroscience.

[176]  G Bernardi,et al.  Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons , 2001, Neuroscience.

[177]  J. Gewirtz,et al.  A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex , 2001, Neuroscience.

[178]  S. Nakanishi,et al.  Regulation of mglu(7) receptors by proteins that interact with the intracellular C-terminus. , 2001, Trends in pharmacological sciences.

[179]  L. Prézeau,et al.  BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. , 2001, Molecular pharmacology.

[180]  P. Conn,et al.  Activation of group III mGluRs inhibits GABAergic and glutamatergic transmission in the substantia nigra pars reticulata. , 2001, Journal of neurophysiology.

[181]  F. Gasparini,et al.  Potential anxiolytic‐ and antidepressant‐like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist , 2001, British journal of pharmacology.

[182]  D. Jane,et al.  (S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord , 2001, Neuropharmacology.

[183]  F. Moroni,et al.  Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges , 2001, British journal of pharmacology.

[184]  P. Spano,et al.  Identification of novel alternatively-spliced mRNA isoforms of metabotropic glutamate receptor 6 gene in rat and human retina. , 2001, Gene.

[185]  W. Spooren,et al.  Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. , 2000, The Journal of pharmacology and experimental therapeutics.

[186]  P. Ornstein,et al.  Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl)glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[187]  K. Ray,et al.  Cys-140 Is Critical for Metabotropic Glutamate Receptor-1 Dimerization* , 2000, The Journal of Biological Chemistry.

[188]  F. Gasparini,et al.  The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors* , 2000, The Journal of Biological Chemistry.

[189]  S. Nakanishi,et al.  Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor , 2000, Nature.

[190]  T. Woltering,et al.  Characterization of [3H]-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using Semliki Forest virus vectors , 2000, Neuropharmacology.

[191]  W. Spooren,et al.  Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. , 2000, European journal of pharmacology.

[192]  N. Chaudhari,et al.  A metabotropic glutamate receptor variant functions as a taste receptor , 2000, Nature Neuroscience.

[193]  Xi-Ping Huang,et al.  Probing the Ligand-binding Domain of the mGluR4 Subtype of Metabotropic Glutamate Receptor* , 1999, The Journal of Biological Chemistry.

[194]  Roland Heckendorn,et al.  2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist , 1999, Neuropharmacology.

[195]  D. Jane,et al.  Pharmacological agents acting at subtypes of metabotropic glutamate receptors , 1999, Neuropharmacology.

[196]  D. Schoepp,et al.  The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. , 1999, The Journal of pharmacology and experimental therapeutics.

[197]  A. Malhotra,et al.  Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. , 1999, The American journal of psychiatry.

[198]  P. Ornstein,et al.  [3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells , 1999, Neuropharmacology.

[199]  P. Worley,et al.  Coupling of mGluR/Homer and PSD-95 Complexes by the Shank Family of Postsynaptic Density Proteins , 1999, Neuron.

[200]  F. Gasparini,et al.  SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. , 1999, The Journal of pharmacology and experimental therapeutics.

[201]  K. Rhodes,et al.  Immunohistochemical localization of subtype 4a metabotropic glutamate receptors in the rat and mouse basal ganglia , 1999, The Journal of comparative neurology.

[202]  R. Faull,et al.  Cloning and functional expression of alternative spliced variants of the human metabotropic glutamate receptor 8. , 1999, Brain research. Molecular brain research.

[203]  R. Masgrau,et al.  Group I Metabotropic Glutamate Receptors Mediate Phospholipase D Stimulation in Rat Cultured Astrocytes , 1999, Journal of neurochemistry.

[204]  J. Grutsch,et al.  Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. , 1999, Journal of medicinal chemistry.

[205]  F. Gasparini,et al.  CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. , 1999, Molecular pharmacology.

[206]  F. Nicoletti,et al.  Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors , 1999, Neuropharmacology.

[207]  M. Caron,et al.  Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. , 1999, Science.

[208]  F. Ferraguti,et al.  Cloning and characterization of alternative mRNA forms for the rat metabotropic glutamate receptors mGluR7 and mGluR8 , 1998, The European journal of neuroscience.

[209]  R. J. Sayer.  Group I metabotropic glutamate receptors mediate slow inhibition of calcium current in neocortical neurons. , 1998, Journal of neurophysiology.

[210]  J. Bockaert,et al.  Comparative effect of l-CCG-I, DCG-IV and γ-carboxy-l-glutamate on all cloned metabotropic glutamate receptor subtypes , 1998, Neuropharmacology.

[211]  Y. Kubo,et al.  Structural basis for a Ca2+-sensing function of the metabotropic glutamate receptors. , 1998, Science.

[212]  R. Duvoisin,et al.  Role of the Second and Third Intracellular Loops of Metabotropic Glutamate Receptors in Mediating Dual Signal Transduction Activation* , 1998, The Journal of Biological Chemistry.

[213]  P. Ornstein,et al.  LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors , 1998, Neuropharmacology.

[214]  P. Krogsgaard‐Larsen,et al.  Pharmacology of (S)‐homoquisqualic acid and (S)‐2‐amino‐5‐phosphonopentanoic acid [(S)‐AP5] at cloned metabotropic glutamate receptors , 1998, British journal of pharmacology.

[215]  G. Collingridge,et al.  (RS)-2-Chloro-5-Hydroxyphenylglycine (CHPG) Activates mGlu5, but not mGlu1, Receptors Expressed in CHO Cells and Potentiates NMDA Responses in the Hippocampus , 1997, Neuropharmacology.

[216]  P. O'Hara,et al.  Cloning and Characterization of a Metabotropic Glutamate Receptor, mGluR4b , 1997, Neuropharmacology.

[217]  H. Tse,et al.  Potent antagonists at the L-AP4- and (1S,3S)-ACPD-sensitive presynaptic metabotropic glutamate receptors in the neonatal rat spinal cord , 1996, Neuropharmacology.

[218]  C. Romano,et al.  Metabotropic Glutamate Receptor 5 Is a Disulfide-linked Dimer* , 1996, The Journal of Biological Chemistry.

[219]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[220]  T. Knöpfel,et al.  The Second Intracellular Loop of Metabotropic Glutamate Receptor 1 Cooperates with the Other Intracellular Domains to Control Coupling to G-proteins (*) , 1996, The Journal of Biological Chemistry.

[221]  Carol A. Tamminga,et al.  Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.

[222]  J. Bockaert,et al.  Molecular, functional, and pharmacological characterization of the metabotropic glutamate receptor type 5 splice variants: comparison with mGluR1 , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[223]  D. Schoepp,et al.  Enzymatic resolution and pharmacological activity of the enantiomers of 3,5-dihydroxyphenylglycine, a metabotropic glutamate receptor agonist , 1995 .

[224]  J Staudinger,et al.  PICK1: a perinuclear binding protein and substrate for protein kinase C isolated by the yeast two-hybrid system , 1995, The Journal of cell biology.

[225]  D. Schoepp,et al.  3,5‐Dihydroxyphenylglycine Is a Highly Selective Agonist for Phosphoinositide‐Linked Metabotropic Glutamate Receptors in the Rat Hippocampus , 1994, Journal of neurochemistry.

[226]  H. Sugiyama,et al.  Molecular cloning and the functional expression of two isoforms of human metabotropic glutamate receptor subtype 5. , 1994, Biochemical and biophysical research communications.

[227]  S. Heinemann,et al.  Domains involved in the specificity of G protein activation in phospholipase C‐coupled metabotropic glutamate receptors. , 1994, The EMBO journal.

[228]  H. Shinozaki,et al.  A novel metabotropic glutamate receptor agonist: marked depression of monosynaptic excitation in the newborn rat isolated spinal cord , 1993, British journal of pharmacology.

[229]  J. Sutcliffe,et al.  Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox , 1991, Cell.

[230]  Ben A. Oostra,et al.  Absence of expression of the FMR-1 gene in fragile X syndrome , 1991, Cell.

[231]  D. Schoepp,et al.  Comparison of (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD)- and 1R,3S-ACPD-stimulated brain phosphoinositide hydrolysis. , 1991, European journal of pharmacology.

[232]  J. Pettegrew,et al.  Possible roles of L-phosphoserine in the pathogenesis of Alzheimer's disease. , 1991, Molecular and chemical neuropathology.

[233]  M. Johnston,et al.  In Vitro and In Vivo Pharmacology of trans‐ and cis‐(±)‐1‐Amino‐1,3‐Cyclopentanedicarboxylic Acid: Dissociation of Metabotropic and Ionotropic Excitatory Amino Acid Receptor Effects , 1991, Journal of neurochemistry.

[234]  O. Manzoni,et al.  (trans)-1-amino-cyclopentyl-1,3-dicarboxylate stimulates quisqualate phosphoinositide-coupled receptors but not ionotropic glutamate receptors in striatal neurons and Xenopus oocytes. , 1990, Molecular pharmacology.

[235]  P. Conn,et al.  Selective activation of phosphoinositide hydrolysis by a rigid analogue of glutamate , 1990, Neuroscience Letters.

[236]  C. Cotman,et al.  Trans-ACPD, a selective agonist of the phosphoinositide-coupled excitatory amino acid receptor. , 1989, European journal of pharmacology.

[237]  J. Pecknold,et al.  Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. , 1982, Journal of clinical psychopharmacology.

[238]  K. Gregory,et al.  Pharmacology of metabotropic glutamate receptor allosteric modulators: structural basis and therapeutic potential for CNS disorders. , 2013, Progress in molecular biology and translational science.

[239]  Young Ho Suh,et al.  Regulation of Metabotropic Glutamate Receptor 7 (mGluR7) Internalization and Surface Expression by Ser/Thr Protein Phosphatase 1* , 2013, The Journal of Biological Chemistry.

[240]  P. Conn,et al.  Metabotropic glutamate receptors for new treatments in schizophrenia. , 2012, Handbook of experimental pharmacology.

[241]  Daniela Berg,et al.  Treatment of Levodopa-Induced Dyskinesias : Results of 2 Randomized Controlled Trials , 2011 .

[242]  S. Jadhav,et al.  Discovery of N-Aryl Piperazines as Selective mGlu(5) Potentiators with Efficacy in a Rodent Model Predictive of Anti-Psychotic Activity. , 2010, ACS medicinal chemistry letters.

[243]  J. Kew,et al.  Synthesis and characterization of 8-ethynyl-1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: part 2. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists. , 2008, Bioorganic & medicinal chemistry letters.

[244]  F. Acher,et al.  Amino acid recognition by Venus flytrap domains is encoded in an 8‐residue motif , 2005, Biopolymers.

[245]  R. Liberman.  Drug and psychosocial curricula for psychiatry residents for treatment of schizophrenia: part II. , 2005, Psychiatric services.

[246]  A. Porcellini,et al.  Role of G protein-coupled receptor kinase 4 and beta-arrestin 1 in agonist-stimulated metabotropic glutamate receptor 1 internalization and activation of mitogen-activated protein kinases. , 2003, The Journal of biological chemistry.

[247]  A. Caricasole,et al.  Native group-III metabotropic glutamate receptors activate the mitogen-activated protein kinase/phosphatidylinositol-3-kinase pathways in cultured cerebellar granule cells. , 2002 .

[248]  S. Mennerick,et al.  Covalent and noncovalent interactions mediate metabotropic glutamate receptor mGlu5 dimerization. , 2001, Molecular pharmacology.

[249]  D. Lovinger,et al.  Rat group I metabotropic glutamate receptors inhibit neuronal Ca2+ channels via multiple signal transduction pathways in HEK 293 cells. , 1998, Journal of neurophysiology.

[250]  J. Benovic,et al.  The role of receptor kinases and arrestins in G protein-coupled receptor regulation. , 1998, Annual review of pharmacology and toxicology.

[251]  J. Pin,et al.  Pharmacology and functions of metabotropic glutamate receptors. , 1997, Annual review of pharmacology and toxicology.

[252]  J. Watkins,et al.  Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. , 1990, Trends in pharmacological sciences.